Published on 24/12/2025
Setting Up Virtual Visit Technology for Regulatory Compliance
Introduction: Why Technology Setup is Crucial for Virtual Site Visits
As clinical trials increasingly adopt decentralized and remote models, virtual site visits have become central to trial oversight. However, poorly planned technology infrastructure can lead to regulatory violations, data breaches, and failed inspections. The FDA, EMA, and ICH all expect sponsors to validate, document, and secure virtual visit tools in alignment with GCP and Part 11 requirements.
This article presents a step-by-step guide to setting up technology for virtual visits—from selecting compliant platforms to creating audit trails and implementing CAPA when failures occur.
Step 1: Choose a Part 11-Compliant Platform for Remote Visits
The first decision in enabling virtual site visits is selecting a secure and validated video conferencing and document sharing platform. Some commonly used platforms include:
| Platform | Compliance Features | Notes |
|---|---|---|
| Zoom for Healthcare | HIPAA, 21 CFR Part 11, session recording, data encryption | Requires business associate agreement (BAA) |
| Microsoft Teams (Enterprise) | Multi-factor authentication, logging, screen sharing control | Part 11 validation must be documented internally |
| Webex Meetings | Session recording, identity verification, SSO integration | Less popular in regulated trials, but viable |
All tools must be validated with documented user requirements, test cases,
Step 2: Implement Access Control and Secure Login Protocols
Remote monitoring involves sensitive data like eSource, ICFs, and protocol deviation logs. Therefore, secure access policies are critical:
- VPN Access: Limit CRA access to sponsor-approved VPN connections.
- MFA: Require Multi-Factor Authentication for all remote systems.
- Session Logs: All sessions should generate automatic logs with time stamps and user credentials.
- Temporary Access Windows: Restrict site access to scheduled visit time only.
Tools like Citrix ShareFile or SFTP portals can be used to share blinded documents with limited expiration time.
Step 3: Validate the Remote Source Data Review Process
Virtual visits often involve source data verification (SDV) or source data review (SDR). The following controls should be in place:
- Screen-sharing sessions should be live and not recorded, unless explicitly permitted.
- Use watermarking and disable downloads for sensitive patient data.
- Maintain a separate log indicating documents reviewed and who presented them.
- Review tools must include session validation like timestamps and access logs.
According to the Japanese PMDA, a 2022 inspection cited a sponsor for failing to maintain logs of SDR sessions conducted over unsecured video calls.
Step 4: Integrate Virtual Visit Tools with the eTMF
Inspection readiness depends on seamless integration of virtual visit documentation into the electronic Trial Master File (eTMF). Here’s how to ensure alignment:
- Use standard artifacts: e.g., 05.04.04 – Monitoring Visit Report (Remote)
- Ensure version-controlled SOPs for virtual visit documentation
- Use audit-ready formats (PDF/A) with timestamped signatures
- Ensure metadata entry fields for visit type (remote/hybrid), CRA ID, and platform used
Systems like Veeva Vault and Wingspan support automatic mapping of uploaded reports to eTMF artifact structure and indexing them under the visit cycle.
Step 5: Train CRAs and Site Personnel on Tech Setup
The best technology setup is only as effective as the personnel using it. Common failures occur when CRAs or site staff are not properly trained on new platforms.
- Create site readiness checklists including internet bandwidth, firewall access, and document preparation
- Perform a dry run session with each site prior to the first remote visit
- Maintain documentation of CRA training completion in LMS or training logs
- Use troubleshooting SOPs to resolve common tech issues (e.g., audio lag, screen freeze, password errors)
A CAPA should be triggered if a visit is delayed or rescheduled due to technology failure and logged in the central tracker with root cause analysis.
Case Study: Remote Visit Technology Failure in a Diabetes Trial
Background: A Phase III diabetes study used a hybrid oversight model. The CRA attempted a virtual visit using Microsoft Teams, but due to firewall issues, the session could not proceed.
Inspection Outcome: During a routine FDA inspection, it was found that the visit report simply stated “Session could not be completed – technical failure” without CAPA documentation or rescheduling.
CAPA Actions Taken:
- Revised SOP to mandate documentation of root cause and scheduling of follow-up visit
- Developed a “Tech Incident Log” with timestamped records and CRA comments
- Mandatory site tech verification prior to each remote session
Technology Readiness Checklist
| Checklist Item | Status |
|---|---|
| Platform validated and Part 11 compliant | ✔️ |
| VPN and MFA access protocols documented | ✔️ |
| Pre-visit tech checklist completed | ✔️ |
| CRAs trained on virtual visit SOPs | ✔️ |
| eTMF integrated with report templates | ✔️ |
Conclusion: Making Virtual Visit Technology Inspection-Ready
Technology can either strengthen or weaken your compliance position in virtual site visits. Regulatory expectations require platforms to be secure, validated, and documented. Moreover, successful virtual oversight depends on a clear strategy that aligns SOPs, CAPA workflows, training modules, and infrastructure audits.
By following this guide, sponsors and CROs can ensure their virtual visit setup meets the standards of the FDA, EMA, ICH, and other global regulators—and is ready for inspection at any time.